AC8 has lost its competitive edge.... they can brag about their licences and proprietary hard-capsule trials.. but let's face, you dont have anything to sell. Other MC companies who were lagging behind in 2017-2018 have reported progress and some are actually generating revenue already.
Sadly, 2 years on.... AC8 management is still talking about the SAME sheet they talked about in 2017.
On a valuation basis, i hate to admit but I reckon this could slide back to the 20s or lower.... Lets take emotion out of the equation for a bit. Other than partnerships and licences, as a standalone company, IT HAS NOTHING.
AC8 Price at posting:
31.0¢ Sentiment: Sell Disclosure: Held